EP2144871B1 - Amidation process for the preparation of cathepsin k inhibitors - Google Patents
Amidation process for the preparation of cathepsin k inhibitors Download PDFInfo
- Publication number
- EP2144871B1 EP2144871B1 EP08733702.8A EP08733702A EP2144871B1 EP 2144871 B1 EP2144871 B1 EP 2144871B1 EP 08733702 A EP08733702 A EP 08733702A EP 2144871 B1 EP2144871 B1 EP 2144871B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- batch
- water
- base
- solvent
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 0 *[C@](c(cc1)ccc1-c1ccc(*)cc1)N=C(*)C(NC1(CC1)C#N)=O Chemical compound *[C@](c(cc1)ccc1-c1ccc(*)cc1)N=C(*)C(NC1(CC1)C#N)=O 0.000 description 3
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a base to yield amides, without loss of optical purity.
- the resulting amides are selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and metastatic bone disease.
- WO-A-2006034004 (Axys Pharmaceuticals, Inc.) discloses making deoxy-odanacatib through the conversion of an acid via an activated acid and reaction with an aminocarbonitrile into the final compound.
- EDC is given as an example of a coupling agent.
- WO-A-2005021487 and WO-A-2005019161 disclose processes which first form N-1-(4-bromophenyl)-ethyl-leucinamide derivatives using DIPEA, HOBt and TOTU as coupling reagents, followed by replacing the bromine with a methylthio group.
- WO-A-2003075836 (Merck Frosst Canada and Axys Pharmaceuticals, Inc.) discloses a process using HATU as coupling agent.
- processes for the preparation of compounds of structural formula I comprising amidating a salt of formula IIA or an acid of formula IIB with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent; wherein R 1 is (2-fluoro,2-methyl)propyl; R2 is trifluoromethyl; R3 is SO 2 CH 3 ; X is a tertiary amine, a secondary amine or a metal salt; and m is an integer from zero to two.
- a coupling agent which is EDC, a base and a solvent
- X is a secondary amine.
- X is DCHA.
- the compound of formula I is N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide.
- An ⁇ -aminoacid or its corresponding salt is activated, followed by treatment with an amine in the presence of a base.
- Activation may be achieved by formation of an acyl halide, mixed anhydride or by treatment with a coupling agent, with or without an additional activating agent, in the presence of a suitable base and in a suitable solvent.
- the activating agent is HOBt, N -hydroxy succinimide, 2-hydroxypyridine, N -hydroxyphthalimide or CDI. In a class of the invention, the activating agent is HOBt.
- the base is N -methyl morpholine, TEA, N- ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine.
- the base is N -methyl morpholine.
- the solvent is DMF, DMAc, NMP, acetonitrile, THF, or DMSO.
- the solvent is DMF.
- a compound of structural formula: comprising amidating a salt: with 1-aminocyclopropane carbonitrile, in the presence of EDC, HOBt, N -methyl morpholine and DMF.
- tertiary amine includes, but is not limited to, trimethylamine, triethylamine, tripropylamine, dimethylethanolamine and bis-tris.
- second amine includes, but is not limited to, dimethyl amine, diethylamine, methylethanolamine, aziridine, azetidine, pyrrolidine, piperidine, and dicyclohexylamine (DCHA).
- metal salt includes, but is not limited to, salts of aluminum, antimony, calcium, copper, gold, iron, lead, lithium, magnesium, platinum, potassium, sodium, silver, strontium, tin, titanium, tungsten and zinc.
- Preferred metal salts include salts of lithium, sodium, potassium, magnesium, calcium, aluminum and zinc.
- carbodiimide refers to a class of coupling agents that are often used to activate carboxylic acids towards amide formation.
- Nonlimiting examples or carbodiimides include: DCC (N,N'-dicyclohexylcarbodiimide), DIC (N,N'-diisopropylcarbodiimide) and EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride).
- Crystalline N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide is characterized by an X-ray powder diffraction (XRPD) pattern, collected using copper K ⁇ radiation, corresponding to characteristic reflection peaks at 19.7. 20.1 and 17.6 degrees. The pattern is further characterized by characteristic reflection peaks at 23.6,17.9 and 19.1 degrees. The pattern is further characterized by characteristic reflection peaks at 24.8, 11.7 and 11.9 degrees.
- XRPD X-ray powder diffraction
- the XRPD patterns are measured using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector, CuKa source at a generator power of 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm).
- Scan range is set from 2-40°2 ⁇ with a step size of 0.02° and a count time of 2 seconds.
- the sample is measured on a quartz disk with spinning to reduce potential in-plane orientation effects. Peak positions are verified weekly using a standard corundum plate (NIST SRM 1976).
- crystalline N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide is characterized by melting onset at 214°C.
- Amorphous N 1 -(1-cyanocyclopropyl)-4-fluoro- N 2 - ⁇ (1 S )-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl ⁇ -L-leucinamide can also be observed.
- Scheme 1 depicts the reaction of a substituted ⁇ -amino acid or its salt with an amine in the presence of a coupling agent, an activator and a base to yield the corresponding ⁇ -amino amide product without epimerization of the ⁇ -stereocenter.
- Biphenyl acid (20.74 g) was dissolved in 2-propanol (186 mL) / water (20.7 mL).
- DCHA salt (10 mg)
- a heavy seed bed formed and the slurry was let stir at rt for 30 min. Addition of DCHA was continued over 20-30 min. The slurry was let stir at rt overnight and filtered.
- the filter cake was washed with 2-propanol / water (2 ⁇ 30 mL, 10:1) and MTBE (2 ⁇ 30 mL).
- the batch was then heated to 58-62°C and aged for 1 hour. Following age, water (375 g) was charged over 3 hours, at a rate of 2.1 g/min. The batch was then cooled to 15-25°C and aged overnight. The batch was filtered and washed with 39% DMF in water (2 ⁇ 300 g) and 2-propanol (180 g). The solids were dried in the filter at 40-60°C for 24 hours. The desired crude product was isolated as a white solid (57g, 92% yield, 99.4 wt%). A round-bottom flask was charged with crude solid (57 g) and acetone/water solution (324 g, 88/12).
- the slurry was then heated to 40°C, at which point the batch was in solution, and aged for an hour. Water (46 g) was then charged over 30 minutes. The batch was then seeded (1.7 g, 3.0 wt%), and the batch was aged at 40°C for an hour prior to proceeding with the crystallization. Water (255 g) was charged over 4.5 h. The batch was then cooled to 23°C over 1.5 h, aged for 4 h and filtered. The solids were washed with acetone/water (158 g, 45/55) and water (176 g). The filter cake was dried with nitrogen sweep / vacuum at 55°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
- This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a base to yield amides, without loss of optical purity. The resulting amides are selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and metastatic bone disease.
-
WO-A-2006034004 (Axys Pharmaceuticals, Inc.) discloses making deoxy-odanacatib through the conversion of an acid via an activated acid and reaction with an aminocarbonitrile into the final compound. EDC is given as an example of a coupling agent. -
WO-A-2005021487 andWO-A-2005019161 (both to Merck Frosst Canada & Co.) disclose processes which first form N-1-(4-bromophenyl)-ethyl-leucinamide derivatives using DIPEA, HOBt and TOTU as coupling reagents, followed by replacing the bromine with a methylthio group. -
WO-A-2003075836 (Merck Frosst Canada and Axys Pharmaceuticals, Inc.) discloses a process using HATU as coupling agent. - By this invention, there are provided processes for the preparation of compounds of structural formula I:
comprising amidating a salt of formula IIA or an acid of formula IIB with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent;
wherein R1 is (2-fluoro,2-methyl)propyl;
R2 is trifluoromethyl;
R3 is SO2CH3;
X is a tertiary amine, a secondary amine or a metal salt; and
m is an integer from zero to two. -
-
FIGURE 1 is a characteristic X-ray diffraction pattern of crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide. -
FIGURE 2 is a typical differential scanning calorimetry (DSC) curve of crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide. -
FIGURE 3 is a typical differential scanning calorimetry (DSC) curve of amorphous N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide. - In an embodiment of the invention X is a secondary amine. In a class of the invention, X is DCHA.
-
- An α-aminoacid or its corresponding salt is activated, followed by treatment with an amine in the presence of a base. Activation may be achieved by formation of an acyl halide, mixed anhydride or by treatment with a coupling agent, with or without an additional activating agent, in the presence of a suitable base and in a suitable solvent.
- In an embodiment of the invention, the activating agent is HOBt, N-hydroxy succinimide, 2-hydroxypyridine, N-hydroxyphthalimide or CDI. In a class of the invention, the activating agent is HOBt.
- In an embodiment of the invention, the base is N-methyl morpholine, TEA, N-ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine. In a class of the invention, the base is N-methyl morpholine.
- In an embodiment of the invention, the solvent is DMF, DMAc, NMP, acetonitrile, THF, or DMSO. In a class of the invention, the solvent is DMF.
-
- The term "tertiary amine" includes, but is not limited to, trimethylamine, triethylamine, tripropylamine, dimethylethanolamine and bis-tris.
- The term "secondary amine" includes, but is not limited to, dimethyl amine, diethylamine, methylethanolamine, aziridine, azetidine, pyrrolidine, piperidine, and dicyclohexylamine (DCHA).
- The term "metal salt" includes, but is not limited to, salts of aluminum, antimony, calcium, copper, gold, iron, lead, lithium, magnesium, platinum, potassium, sodium, silver, strontium, tin, titanium, tungsten and zinc. Preferred metal salts include salts of lithium, sodium, potassium, magnesium, calcium, aluminum and zinc.
- The term carbodiimide refers to a class of coupling agents that are often used to activate carboxylic acids towards amide formation. Nonlimiting examples or carbodiimides include: DCC (N,N'-dicyclohexylcarbodiimide), DIC (N,N'-diisopropylcarbodiimide) and EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride).
- Crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide is characterized by an X-ray powder diffraction (XRPD) pattern, collected using copper Kα radiation, corresponding to characteristic reflection peaks at 19.7. 20.1 and 17.6 degrees. The pattern is further characterized by characteristic reflection peaks at 23.6,17.9 and 19.1 degrees. The pattern is further characterized by characteristic reflection peaks at 24.8, 11.7 and 11.9 degrees. The XRPD patterns are measured using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector, CuKa source at a generator power of 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm). Scan range is set from 2-40°2θ with a step size of 0.02° and a count time of 2 seconds. The sample is measured on a quartz disk with spinning to reduce potential in-plane orientation effects. Peak positions are verified weekly using a standard corundum plate (NIST SRM 1976).
- In addition to the X-ray powder diffraction pattern described above, crystalline N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide is characterized by melting onset at 214°C. The DSC thermal behaviour is investigated using a Seiko robotic DSC (RDC-220). DSC analyses (n=2) are carried out in crimped aluminium pans (2, 10, and 20°C/min, 80mL/min nitrogen). The DSC is calibrated for temperature and heat flow with gallium (Goodfellow, 99.99% Pure), indium (Goodfellow, 99.999% Pure), and tin (NIST SRM 2220).
- Amorphous N 1-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide can also be observed. The glass transition temperature for the amorphous form is evaluated by temperature cycling and is measured at the mid-point. The sample are heated from -30°C to 75°C at 10°C/min following by cooling at 10°C/min to -30°C, and then the sample is re-heated to 180°C at 10°C/min (n=1). A glass transition temperature (Tg) of about 64°C (mid-point, 10°C/min) followed by an exothermic transition at a peak temperature of 101°C, attributed to recrystallization of amorphous material, is obtained for a predominantly amorphous sample. The DSC thermal behaviour is investigated using a Seiko robotic DSC (RDC-220). DSC analyses (n=2) are carried out in crimped aluminium pans (2, 10, and 20°C/min, 80mL/min nitrogen). The DSC is calibrated for temperature and heat flow with gallium (Goodfellow, 99.99% Pure), indium (Goodfellow, 99.999% Pure), and tin (NIST SRM 2220).
- In the schemes and examples below, various reagent symbols and abbreviations have the following meanings:
DMAc: N,N'-Dimethyl acetamide DCHA: Dicyclohexylamine MTBE: Methyl-t-butylether iPAc: Isopropyl acetate DMF: N,N'-Dimethylformamide THF: Tetrahydrofuran TEA: Triethylamine DMSO: Dimethylsulfoxide NMP: 1-Methyl-2-pyrrolidinone CDI: N N'-Carbonyldiimidazole HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N'N'-tetramethyluronium hexafluorophosphate EDC: 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride HOBt: N-Hydroxybenzotriazole NMM: N-methyl morphonline -
- The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
-
- Biphenyl acid (20.74 g) was dissolved in 2-propanol (186 mL) / water (20.7 mL). A solution of N,N-dicyclohexylamine (9.82 mL) in 2-propanol (21 mL) / water (2 mL) was added (∼10% of volume) and the solution was seeded with DCHA salt (10 mg). A heavy seed bed formed and the slurry was let stir at rt for 30 min. Addition of DCHA was continued over 20-30 min. The slurry was let stir at rt overnight and filtered. The filter cake was washed with 2-propanol / water (2 × 30 mL, 10:1) and MTBE (2 × 30 mL). DCHA salt was obtained as a white solid, 24.4 g, 84% yield. 1H NMR (CD3OD) δ 8.07 (d, 2H, J = 8.0), 7.94 (d, 2H, J = 8.0), 7.75 (d, 2H, J = 8.0), 7.61 (d, 2H, J= 8.0), 4.31 (m, 1H), 3.46 (bq, 1H, J= 4), 3.22 (m, 2H), 3.19 (s, 3H), 2.11 (bm, 5H), 1.91 (bm, 5H), 1.75 (bm, 2H), 1.49 (d, 3H, J = 21.6), 1.48 (d, 3H, J = 21.6), 1.35 (m, 9H); 19F NMR (CD3OD) δ - 72.9, - 129.4; mp 209-211 °C, [α]D 20 + 18.7 (c = 0.29, MeOH).
-
- Acid (1.9 g) was dissolved in DMAc (10 mL) and cooled to 0°C. 1-Aminocyclopropane carbonitrile hydrochloride (0.57 g) and HATU (1.85 g) were added. The resulting slurry was stirred for 15 min and DIEA (2.12 mL) was added over 1.5 h. The reaction was aged for 1 h. Water (11.2 mL) was added via dropping funnel over 70 min and the slurry was aged for 1h at 20°C. The mixture was filtered and the filter cake was washed with a solution of DMAc:water (9.4 mL, 1:1.2), water (18.7 mL), 2-propanol (9.3 mL) The batch was dried to yield 1.67 g, 79% yield of the corresponding amide.
- Amide (2.56 g), was dissolved in THF (30.7 mL) at 30°C. Water (19 mL) was added via dropping funnel. The batch was seeded and aged for 1h at 20°C. Additional water (40.9 mL) was added over 1.5 h and the batch was aged for 16 h. The batch was filtered and washed with water (15 mL). The solids were dried to a constant weight to yield 2.50 g, 97% yield of pure amide. 1H NMR (CD3OD) δ 8.17 (bs, 1H), 8.05 (d, 2H, J= 8.5), 7.96 (d, 2H, J = 8.5), 7.80 (d, 2H, J = 8.0), 7.64 (d, 2H, J= 8.0), 4.43 (m, 1H), 3.55 (ddd, 1H, J = 5.0, 8.5, 8.0), 3.18 (s, 3H), 2.84 (bm, 1H), 2.02 (m, 2H), 1.46 (d, 3H, J = 21.5), 1.43 (d, 3H, J = 22.0), 1.36 (m, 2H), 1.07 (m, 1H), 0.94 (m, 1H); 13C NMR (CD3OD) δ; 19F NMR (CD3OD) δ -73.2, -136.8; IR (cm-1) 3331, 2244, 1687, 1304, 1152; mp 223-224 °C, [α]D 20 + 23.3 (c = 0.53, MeOH).
-
- A round-bottom flask was charged with biphenyl acid•DCHA salt (76.6 g, 99.2% ee, diastereomeric ratio 342:1) and DMF (590 g). Solid aminocyclopropane carbonitrile•HCl (15.2 g), HOBt•H2O (17.9 g), and EDC•HCl (29.1 g) were all charged forming a white slurry. The batch was then heated to 38-42°C and aged for 5 hours. The batch was then cooled to 20-25°C and held overnight. HPLC analysis showed 99.4% conversion. The batch was heated to 38-42°C and water (375 g) was charged to batch over 2 hours. The batch remained as a slurry throughout the water addition. The batch was then heated to 58-62°C and aged for 1 hour. Following age, water (375 g) was charged over 3 hours, at a rate of 2.1 g/min. The batch was then cooled to 15-25°C and aged overnight. The batch was filtered and washed with 39% DMF in water (2 × 300 g) and 2-propanol (180 g). The solids were dried in the filter at 40-60°C for 24 hours. The desired crude product was isolated as a white solid (57g, 92% yield, 99.4 wt%). A round-bottom flask was charged with crude solid (57 g) and acetone/water solution (324 g, 88/12). The slurry was then heated to 40°C, at which point the batch was in solution, and aged for an hour. Water (46 g) was then charged over 30 minutes. The batch was then seeded (1.7 g, 3.0 wt%), and the batch was aged at 40°C for an hour prior to proceeding with the crystallization. Water (255 g) was charged over 4.5 h. The batch was then cooled to 23°C over 1.5 h, aged for 4 h and filtered. The solids were washed with acetone/water (158 g, 45/55) and water (176 g). The filter cake was dried with nitrogen sweep / vacuum at 55°C. The desired product (57.2 g , 99.9wt%, 99.8A% (enantiomer ND), was obtained in 94.9% yield. 1H NMR (CD3OD) δ 8.17 (bs, 1H), 8.05 (d, 2H, J = 8.5), 7.96 (d, 2H, J = 8.5), 7.80 (d, 2H, J= 8.0), 7.64 (d, 2H, J = 8.0), 4.43 (m, 1H), 3.55 (ddd, 1H, J = 5.0, 8.5, 8.0), 3.18 (s, 3H), 2.84 (bm, 1H), 2.02 (m, 2H), 1.46 (d, 3H, J= 21.5), 1.43 (d, 3H, J= 22.0), 1.36 (m, 2H), 1.07 (m, 1H), 0.94 (m, 1H); 13C NMR (CD3OD) δ; 19F NMR (CD3OD) δ -73.2, -136.8; IR (cm-1) 3331, 2244, 1687, 1304, 1152; mp 223-224 °C, [α]D 20 + 23.3 (c = 0.53, MeOH).
Claims (5)
- A process for preparing a compound of formula I:
comprising amidating a salt of formula IIA or an acid of formula IIB with 1-aminocyclopropane carbonitrile, in the presence of a coupling agent which is EDC, a base and a solvent; wherein R1 is (2-fluoro, 2-methyl) propyl;
R2 is trifluoromethyl;
R3 is SO2 CH3;
X is a tertiary amine, a secondary amine or a metal salt; and
m is an integer from zero to two. - The process of Claim 1 wherein the base is N-methyl morpholine, TEA, N-ethyldiisopropylamine, 2,6-lutidine, 2,4,6 collidine or 1-methylpiperidine.
- The process of Claim 1 or 2 wherein the solvent is DMF, DMAc, NMP, acetonitrile, THF or DMSO.
- The process of Claim 1, 2 or 3 which also comprises an activating agent which is N-hydroxy succinimide, 2-hydroxypyridine, N-hydroxyphthalimide, CDI or HOBt.
- The process of Claim 4 wherein the activating agent is HOBt; the base is N-methyl morpholine; and the solvent is DMF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92132107P | 2007-04-02 | 2007-04-02 | |
| PCT/CA2008/000605 WO2008119176A1 (en) | 2007-04-02 | 2008-03-31 | Amidation process for the preparation of cathepsin k inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2144871A1 EP2144871A1 (en) | 2010-01-20 |
| EP2144871A4 EP2144871A4 (en) | 2011-11-23 |
| EP2144871B1 true EP2144871B1 (en) | 2014-06-25 |
Family
ID=39807759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08733702.8A Not-in-force EP2144871B1 (en) | 2007-04-02 | 2008-03-31 | Amidation process for the preparation of cathepsin k inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8273913B2 (en) |
| EP (1) | EP2144871B1 (en) |
| JP (1) | JP5364695B2 (en) |
| CN (1) | CN101668736B (en) |
| AU (1) | AU2008234380B2 (en) |
| CA (1) | CA2682622A1 (en) |
| WO (1) | WO2008119176A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2681188A4 (en) * | 2011-03-02 | 2015-04-15 | Merck Sharp & Dohme | AMIDATION METHOD |
| CZ2014941A3 (en) | 2014-12-19 | 2016-06-29 | Zentiva, K.S. | Preparation process of extremely pure intermediate for odanacatib synthesis |
| US10472345B2 (en) | 2016-02-04 | 2019-11-12 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| HRP20040800B1 (en) * | 2002-03-05 | 2012-11-30 | Merck Frosst Canada & Co Axys | Cathepsin cysteine protease inhibitors |
| CA2535359A1 (en) | 2003-08-21 | 2005-03-03 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| EP1660436A4 (en) * | 2003-08-27 | 2006-11-22 | Merck Frosst Canada Ltd | INHIBITORS OF CATHEPSINE |
| KR20070061877A (en) | 2004-09-17 | 2007-06-14 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Methods and Intermediates for the Preparation of Cysteine Protease Inhibitors |
-
2008
- 2008-03-31 WO PCT/CA2008/000605 patent/WO2008119176A1/en not_active Ceased
- 2008-03-31 US US12/593,695 patent/US8273913B2/en not_active Expired - Fee Related
- 2008-03-31 CN CN2008800109878A patent/CN101668736B/en not_active Expired - Fee Related
- 2008-03-31 JP JP2010501337A patent/JP5364695B2/en not_active Expired - Fee Related
- 2008-03-31 EP EP08733702.8A patent/EP2144871B1/en not_active Not-in-force
- 2008-03-31 AU AU2008234380A patent/AU2008234380B2/en not_active Ceased
- 2008-03-31 CA CA002682622A patent/CA2682622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2144871A1 (en) | 2010-01-20 |
| CN101668736B (en) | 2013-06-12 |
| CN101668736A (en) | 2010-03-10 |
| EP2144871A4 (en) | 2011-11-23 |
| JP5364695B2 (en) | 2013-12-11 |
| US20100130782A1 (en) | 2010-05-27 |
| AU2008234380B2 (en) | 2013-01-24 |
| CA2682622A1 (en) | 2008-10-09 |
| US8273913B2 (en) | 2012-09-25 |
| WO2008119176A1 (en) | 2008-10-09 |
| JP2010523500A (en) | 2010-07-15 |
| AU2008234380A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6985367B2 (en) | New compounds and methods | |
| JP6873053B2 (en) | Method for Producing Protein Deacetylation Inhibitor | |
| JP2024503855A (en) | Method for synthesizing aminopyrimidine-based FAK inhibitor compounds | |
| EP2144871B1 (en) | Amidation process for the preparation of cathepsin k inhibitors | |
| EP3280721B1 (en) | Process for preparation of nitrogen mustard derivatives | |
| JP2019147763A (en) | Manufacturing method of proline amide compound | |
| CN1188475A (en) | Guanidine derivatives, their intermediates and their products | |
| US20170066715A1 (en) | Amidation process | |
| TWI545114B (en) | Method for preparing biphenyl imidazole compound | |
| US8278484B2 (en) | Process for preparing a benzoylbenzeneacetamide derivative | |
| WO2009090663A1 (en) | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof | |
| JP7693921B2 (en) | Method for producing prolinamide compound | |
| JP2010083888A (en) | Method for preparing azelnidipine crystal | |
| EP4349847A1 (en) | Process and intermediates for preparation of omaveloxolone and salts thereof | |
| HK1250732B (en) | Process for preparation of nitrogen mustard derivatives | |
| CN108727212A (en) | A kind of synthesis of Mirabegron intermediate (R) -2- hydroxy-ns-(4- nitrophenethyls) -2- phenyl-acetamides | |
| NZ736564B2 (en) | Process for preparation of nitrogen mustard derivatives | |
| GB2552697A (en) | Process for the preparation of boscalid | |
| JP2005247824A (en) | Method for producing 3-acylaminobenzofuran-2-carboxylic acid derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20091102 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK CANADA INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20111024 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/04 20060101ALI20111019BHEP Ipc: C07C 317/32 20060101ALI20111019BHEP Ipc: C07B 43/06 20060101ALI20111019BHEP Ipc: A61K 31/277 20060101ALI20111019BHEP Ipc: C07C 315/04 20060101AFI20111019BHEP Ipc: A61P 19/10 20060101ALI20111019BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK CANADA INC. |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK CANADA INC. |
|
| 17Q | First examination report despatched |
Effective date: 20130423 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20140204 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 674587 Country of ref document: AT Kind code of ref document: T Effective date: 20140715 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008032977 Country of ref document: DE Effective date: 20140807 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140925 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140926 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 674587 Country of ref document: AT Kind code of ref document: T Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141027 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141025 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008032977 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20150326 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150331 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20170222 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080331 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170223 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20170331 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140625 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008032977 Country of ref document: DE |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181002 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 |